Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.63 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.61 |
| ▸ | IGF1R | P08069 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | IAPP | P10997 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089814 | 0.86 | TRPA1 (0.81) | TRPV1TRPA1 | |
| SCHEMBL3085102 | 0.85 | TRPV1 (0.84) | TRPV1TRPA1 | |
| SCHEMBL3103159 | 0.85 | TRPV1 (0.84) | TRPV1TRPA1 | |
| SCHEMBL28104562 | 0.80 | POLB (0.74) | TRPV1TRPA1IGF1RALOX15POLB | |
| 2-Hydroxy-1,7-Di-(4-Hydroxy-Phenyl)-Heptan-4-One (Enantiomeric Mix) SCHEMBL3105208 | 0.79 | TRPV1 (0.73) | TRPV1TRPA1ACHESGMS1SGMS2 | |
| SCHEMBL3103285 | 0.77 | TRPA1 (1.00) | TRPV1TRPA1POLBGAA | |
| SCHEMBL3094426 | 0.76 | TRPV1 (1.00) | TRPV1TRPA1POLBGAA | |
| SCHEMBL3098651 | 0.76 | TRPV1 (1.00) | TRPV1TRPA1POLBGAA | |
| SCHEMBL3090877 | 0.75 | TRPA1 (0.72) | TRPV1TRPA1POLBGAAIAPP | |
| Hirsutanonol SCHEMBL1816532 | 0.75 | POLB (0.63) | TRPV1TRPA1POLBGAAIAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA | 2010-09-30 | — | — | US | disclosed |
| EP-2227449-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | Pulkkinen, Juha (FI) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009066008-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009066008-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | PULKKINEN JUHA (FI) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249243-A1 | NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY | HSD17B11, HSD17B7, CYP19A1 | TRPV1 3501/4885TRPA1 4348/4885IGF1R 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.